L-Annamycin + Cytarabine in Relapsed/Refractory AML

Adaptive Ph2/3 randomized double-blind placebo-controlled design with Part A (1:1:1 randomization) selecting optimal L-Annamycin dose (190 vs 230 mg/m2) by CR rate before Part B superiority test. r/r AML after 1 prior line is challenging population but primary CR endpoint after 1 cycle (to day 49) is objective and early. Prior Ph1/2 showed 36-60% CR/CRi in 2L setting; preliminary blinded CRc 40% (

Relapsed/refractory AML is a high-risk indication with historically low response rates. L-Annamycin is an anthracycline with prior clinical data but faces stiff competition from newer agents (venetoclax, FLT3 inhibitors). The adaptive Phase 2/3 design is rigorous, but complete remission as endpoint in this difficult population is ambitious. Estimated 35% intrinsic probability.

L-Annamycin is a novel anthracycline from micro-cap Moleculin (MBRX). Phase 1B/2 showed promising 50% CR in 2L and 40% blinded CRc in first 30 MIRACLE pts. However: tiny sponsor with limited resources, R/R AML is extremely difficult, trial is only recruiting (1206 days to completion), adaptive Phase 2/3 design adds complexity, and 312-patient enrollment across multiple countries is ambitious for MBRX. Prior Phase 2 data is encouraging but small (n=22). Interim unblinding mid-2026 is a near-term catalyst but final results are years away.

Pivotal AML trial faces high historical failure rates for R/R patients. While L-annamycin's non-cardiotoxic profile is promising, the primary endpoint of CR rate after one cycle is aggressive. Phase 2/3 adaptive design introduces operational complexity and placebo-controlled superiority is a high bar. Dose selection in Part A adds risk before Part B expansion.

Adaptive randomized blinded design and a remission endpoint in relapsed AML are sensible, but this is an early pivotal program with dose-selection complexity, small biotech execution risk, and a long path before a definitive superiority readout.

Adaptive pivotal design in high-risk r/r AML is challenging. Primary endpoint is objective (CR rate), but L-Annamycin's prior data is limited. Sponsor is small-cap. Part A dose selection adds complexity. Overall odds are below 50%.

R/R AML is a notoriously difficult indication with a high historical failure rate in pivotal trials. While Annamycin's design to evade multidrug resistance is interesting, demonstrating statistically significant superiority over placebo + cytarabine in a Phase 3 setting will be highly challenging.

Relapsed/refractory AML after one prior line is a high-mortality population with poor prognosis. L-Annamycin is an anthracycline derivative with limited prior Phase 1/2 data in this exact setting. The adaptive design (Part A dose selection, Part B superiority) introduces execution risk—wrong dose selection dooms Part B. Complete remission after one cycle is a demanding endpoint in this refractory population. 312-patient size is modest for a pivotal claim. Sponsor MBRX is micro-cap with limited track record of pivotal trial execution. Long timeline (1206 days) adds operational and funding risk.

Pivotal adaptive Phase 2/3 trial with uncertain outcomes, limited prior data on L-Annamycin, and high relapse rate in AML patients.